MedTrace Logo

Curcumin, Vitamin D and Green Tea in IBS-D

NCT07052890 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-03-11

No results posted yet for this study

Summary

Irritable Bowel Syndrome (IBS) is a highly prevalent condition of the gastrointestinal tract that has significant impact on sufferer's quality of life. The diarrhoea variant (IBS-D) makes up around one third of all IBS sufferers. There is currently a lack of both effective pharmacological and non-pharmacological treatments for IBS-D.

Three food supplements: Green tea, vitamin D and curcumin have all been shown to demonstrate benefit in either reducing symptoms in IBS or diarrhoea as individual ingredients, but have never been tested in combination to assess their effectiveness in IBS. This research study aims to examine the effectiveness of green tea, vitamin D and curcumin in combination compared to a placebo capsule in individual suffering from IBS-D.

The study will aim to enroll 78 participants with IBS-D and utilise a placebo-controlled double blind design. The study will consist of a 2 week screening period, a 4 week randomised treatment period (50% participants to receive placebo, 50% to receive active treatment), followed by a 4 week open label treatment period (all participants to receive the active study product).

Conditions

  • Irritable Bowel Syndrome (IBS)
  • Irritable Bowel Syndrome With Diarrhea (IBS-D)

Interventions

DIETARY_SUPPLEMENT

Curcumin, vitamin d and green tea extract

A combination of the following ingrediants per 4 capsules: CurcuWin® 1000mg - of which 200mg Curcuminoids Green Tea Extract 400mg - (0.1-0.5% caffeine) Vitamin D₃ 50 µg 2000IU

DIETARY_SUPPLEMENT

Placebo Capsule(s)

Placebo - identical capsules containing inert color matched power

Sponsors & Collaborators

  • Dr Anthony Hobson

    lead OTHER

Principal Investigators

  • Anthony Hobson, PhD · The Functional Gut Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-19
Primary Completion
2025-12-08
Completion
2026-01-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07052890 on ClinicalTrials.gov